Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BioXcel Therapeutics (BTAI) Treasury Shares (2022 - 2025)

Historic Treasury Shares for BioXcel Therapeutics (BTAI) over the last 4 years, with Q3 2025 value amounting to $115000.0.

  • BioXcel Therapeutics' Treasury Shares fell 9357.54% to $115000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $115000.0, marking a year-over-year decrease of 9357.54%. This contributed to the annual value of $70000.0 for FY2024, which is 6888.89% down from last year.
  • BioXcel Therapeutics' Treasury Shares amounted to $115000.0 in Q3 2025, which was down 9357.54% from $77000.0 recorded in Q2 2025.
  • BioXcel Therapeutics' 5-year Treasury Shares high stood at $1.8 million for Q3 2024, and its period low was $60000.0 during Q1 2025.
  • In the last 4 years, BioXcel Therapeutics' Treasury Shares had a median value of $155000.0 in 2022 and averaged $303214.3.
  • As far as peak fluctuations go, BioXcel Therapeutics' Treasury Shares soared by 83717.28% in 2024, and later plummeted by 9357.54% in 2025.
  • Over the past 4 years, BioXcel Therapeutics' Treasury Shares (Quarter) stood at $119000.0 in 2022, then soared by 89.08% to $225000.0 in 2023, then plummeted by 68.89% to $70000.0 in 2024, then surged by 64.29% to $115000.0 in 2025.
  • Its Treasury Shares was $115000.0 in Q3 2025, compared to $77000.0 in Q2 2025 and $60000.0 in Q1 2025.